Eli Lilly has updated its policy regarding expanded access to its unapproved obesity medication, retatrutide. This decision follows weeks of pressure after reports revealed a single, well-connected 79-year-old patient received compassionate use access to the drug. Medical professionals across the country previously struggled to get clear answers from the pharmaceutical manufacturer about similar requests for their own patients.
On Monday, the company confirmed it will now accept applications from a broader group of patients seeking access to the treatment before it receives formal FDA approval. A representative stated that for a limited number of individuals who meet specific medical criteria and cannot enroll in current clinical trials, the company deems it appropriate to provide the medication. This shift aligns with existing FDA guidance for expanded access programs.
This move represents a departure from the company's prior, more opaque approach to the program. While the pharmaceutical giant previously offered minimal information, doctors are now seeing an active review process for these requests. The development highlights the tension between private drug development timelines and the urgent needs of patients living with severe obesity who do not qualify for standardized studies.
Health care providers who have previously hit roadblocks are now encouraged to coordinate with the company to submit requests for their patients. The updated process is intended to provide a pathway for those with significant medical needs while maintaining the integrity of ongoing research protocols. As the industry monitors the demand for such weight-loss therapies, this policy change provides a clearer, albeit limited, route for those seeking treatment outside of conventional trial settings.